Marrite – hormones of gonads and medicaments used at pathology of genitals for treatment of endometriosis.

Structure

• active ingredient: diyenogest micronized;
1 tablet contains
• diyenogest micronized 2 mg;
• other components: lactose, monohydrate; K 30 povidone; starch corn prezhelatinizirovanny; microcrystalline cellulose; krospovidon (type A); silicon dioxide colloidal waterless; magnesium stearate.

Contraindication

Drug Marita should not be used in the presence of any of following states or diseases. This information is partially obtained on the basis of use of other medicines containing only progestogen. If any of these states or diseases arises for the first time at application of the diyenogest, administration of medicament should be stopped immediately.

• Venous thrombembolia in an active form.
• Arterial or cardiovascular diseases now or in the anamnesis (for example, a myocardial infarction, an acute disorder of cerebral circulation, coronary heart disease).
• Diabetes with defeat of vessels.
• Serious illness of a liver now or their existence in the anamnesis until indicators of function of a liver return to norm.
• Tumour of a liver now or in the anamnesis (benign or malignant).
Are known to
• or the suspected malignant tumors depending on sex hormones.
• Vaginal bleeding of the obscure etiology.
• Hypersensitivity to active ingredient or any of medicine components.

Side reactions

Side reactions most often develop within the first months of application of the diyenogest and disappear in the course of treatment. Changes of nature of bleedings, such as krovomazany, irregular bleedings or amenorrhea can be observed.

to

It was reported about the subsequent side reactions during treatment diyenogesty. Side reactions about which it was most often reported at treatment diyenogesty include a headache (9.0%), discomfort in mammary glands (5.4%), oppressed mood (5.1%) and an acne (5.1%).

Route of administration

For oral administration.

to Accept

on 1 tablet every day without interruption in use of medicine approximately at the same time, washing down with a small amount of liquid. A pill can be taken irrespective of food.

should take the Pill regularly irrespective of menstrual bleeding. As soon as tablets from one packing ended, to begin to take a pill from the following packing, without taking a break in use of medicine.

does not have experience of treatment diyenogesty patients with endometriosis longer than 15 months.

Administration of medicament can be begun with

in any day of a menstrual cycle.

before therapy by the medicine Marita should stop application of any hormonal contraceptives. If contraception is necessary, it is necessary to use in addition a non-hormonal method of prevention of pregnancy (for example, a barrier method).

Admission of intake of medicine

in case of the admission of reception of a tablet, vomiting and diarrhea (which took place within 3-4 hours after reception of a tablet) the efficiency of the medicine Marita can decrease. At the admission of reception of one or several pill it is necessary to take 1 tablet as soon as the woman remembers it, and following to accept in usual time. Similar to the tablet which is not absorbed because of vomiting or diarrhea it is necessary to replace with other tablet.

As Marita the medicine containing only progestogen is considered

Feature of application

that special reservations and security measures on use of progestinosoderzhashchy medicines also concern the diyenogest though not all reservations and precautionary measures are based on the corresponding results of clinical trials of this medicine.

Use during pregnancy or feeding by a breast

Pregnancy

limited data on application of the diyenogest to pregnant women Exist. Researches on animals do not indicate direct or indirect risk of reproductive toxicity (see the section "Pharmacological Properties").

Marita Medicine is not recommended to be applied to pregnant women because there is no need to treat endometriosis during pregnancy.

feeding Period

Use of Marita medicine during feeding by a breast is not recommended to

by a breast

. It is unknown whether gets diyenogest into breast milk of the woman. The data obtained in the course of the researches on animals indicate penetration of the diyenogest into breast milk. It is necessary to make the decision on the feeding termination by a breast or the therapy termination by the medicine Marita, considering advantage of feeding by a breast for the child and need of therapy for the woman.

Children

Drug Marita is not shown by

for application to children before menarche.

by

Ability to influence speed of response at control of motor transport or other mechanisms

did not observe influence on ability to steer motor transport and to operate mechanisms at the patients taking the medicaments containing diyenogest.

Overdose

Researches of acute toxicity conducted with diyenogesty did not indicate

risk of development of acute side reactions in case of inadvertent reception of several daily therapeutic doses. No specific antidotes exist. Use of 20-30 mg of the diyenogest to day (is 10-15 times higher, than a dose in a medicine Marita tablet) within more than 24 weeks were transferred very well.

Storage conditions

to Store

in original packing for protection against light.

to Store

out of children's reach.